Manulife (Manufacturers Life Insurance)’s SAB Biotherapeutics SABS Stock Holding History

Manulife (Manufacturers Life Insurance)’s Portfolio SABS Stock Details SABS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$50.5K	Buy	+12,947	New	+$48.2K	﹤0.01%	2850

Other funds holding SABS

Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Manulife (Manufacturers Life Insurance)'s SABS Position: Q2 2026 in Review

Manulife (Manufacturers Life Insurance) opened a new position in SAB Biotherapeutics (SABS) in Q2 2026: 12,947 shares worth $50.5K. The stake represents ﹤0.01% of the portfolio and ranks #2850 among its holdings.

87 funds tracked by Wall St. Rank hold SABS as of Q2 2026.

Manulife (Manufacturers Life Insurance) held 12,947 shares of SAB Biotherapeutics worth $50.5K as of Q2 2026.
SAB Biotherapeutics was a new Manulife (Manufacturers Life Insurance) position in Q2 2026.
SAB Biotherapeutics made up ﹤0.01% of Manulife (Manufacturers Life Insurance)'s portfolio in Q2 2026, its #2850 holding.
87 funds tracked by Wall St. Rank held SAB Biotherapeutics as of Q2 2026.

Based on Manulife (Manufacturers Life Insurance)'s 13F filing for Q2 2026, filed 14 Aug 2026.